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INTRODUCTION

 ypophosphatasia is a rare inherited bone disease resulting from
H
mutations in the gene encoding tissue-nonspecific alkaline
phosphatase (TNSALP), an enzyme predominant in skeleton,
liver, kidney and teeth.
Diminished TNSALP activity causes accumulation of substrates
that inhibit bone mineralization resulting in debilitating pain,
fractures and low alkaline phosphatase (ALP) levels.
In 2015 the FDA approved asfotase alfa, a bone-targeted
recombinant TNSALP, for treatment of infant/child onset
hypophosphatasia.
We present a case of hypophosphatasia treated with asfotase
alfa resulting in improvements in whole body scan and pedometer
step counts.

CASE REPORT

In 2014, a 52-year-old female with chronic pain presented with
over 30 years of bony pain, poor balance, falls, fractures and lifelong dental disease.
Physical exam displayed tenderness of long bones and waddling gait.
Blood work was remarkable for low ALP and low bone-specific
ALP. Vitamin B6 level was significantly elevated. Calcium level
was normal. Serum phosphorus was elevated. Intact parathyroid
hormone level was elevated, with known diagnosis of chronic
kidney disease, GFR 27 mL/min. Her 24-hour urine calcium,
serum protein electrophoresis, celiac test, thyroid studies and
vitamin D level were normal. N-telopeptide was elevated.
SPECT whole body scan demonstrated increased uptake with
multiple fractures of the axial skeleton and proximal femurs;
consistent with oncogenic osteomalacia.
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F ibroblast growth factor 23 and indium 111 octreotide scan
showed no evidence of malignancy.
DEXA scan showed osteopenia of the hip and forearm.
She was diagnosed with hypophosphatasia.
Initially, due to lack of options, she was treated with denosumab.
After three injections, she developed a new atypical femur
fracture requiring surgical rod placement; denosumab was
discontinued.
In 2017, she was started on asfotase alfa with significant
improvements in balance, endurance, and bone pain.
Prior to treatment, the patient required narcotic oral pain
medicine, fentanyl patch and an assistive device to walk 3000
steps daily; after treatment, she is walking over 10,000 steps
daily without any pain pharmacotherapy.
Repeat whole body scan showed less focal uptake overall,
consistent with healing fractures.

2014 WHOLE BODY BONE SCAN

2017 WHOLE BODY BONE SCAN

IMPRESSION:
Extra-axial hyperdense lesion in left frontal region of the calvarium. Multiple
fractures and focal areas of increased uptake in the axial skeleton as well as
fractures of the proximal third of both femurs.

IMPRESSION:
Minimal to mild focal activity at posterior right 10th and 11th rib, proximal left
femur, vertex of skull, and right femur.

TABLE 1.
Test

Result

Normal Value

Alkaline Phosphatase

11 U/L

35-120 U/L

Bone-Specific Alkaline Phosphatase

3 ug/L

7.0-22.4 ug/L

Vitamin B6

>2000 nmol/L 20.0-125.0 nmol/L

Calcium

9.8 mg/dL

8.5-10.1 mg/dL

Phosphorus

5.2 mg/dL

2.3-4.6 mg/dL

Intact Parathyroid Hormone

114.1 pg/mL

18.5-88.0 pg/mL

Parathyroid Hormone Related Peptide 3.4 pmol/L

0.0-3.4 pmol/L

Thyroid stimulating hormone

1.83 ulU/mL

0.35-4.00 ulL/mL

25-OH Vitamin D

42 ng/mL

30-100 ng/mL

N-Telopeptide

25.9 nM

6.2 to 19.0 nM

CONCLUSION

T his case highlights clinical proof of improvement after treatment
with asfotase alfa based on increased daily step count and healing
fractures on whole body scans.

A sfotase alfa is a newly approved therapy for hypophosphatasia and
therefore long-term outcomes are not yet available, however short
term patient reported subjective findings and clinical data are
reassuring for successful treatment.
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